<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876250</url>
  </required_header>
  <id_info>
    <org_study_id>2013-816</org_study_id>
    <nct_id>NCT02876250</nct_id>
  </id_info>
  <brief_title>Postconditioning by Cyclosporin A in Pulmonary Transplantation</brief_title>
  <acronym>CsA Poumon</acronym>
  <official_title>Postconditioning by Cyclosporin A in Pulmonary Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The morbidity and mortality of patients undergoing lung transplantation in the acute phase
      following surgical intervention is mainly due to the primary graft failure (PGF).

      The occurrence of PGF is multi factorial but is mainly caused by ischemia-reperfusion injury.
      The pulmonary graft suffers two periods of ischemia one when it is explanted from the donor
      (cold ischemia) followed by another when it is grafted into the recipient's thoracic cavity
      (warm ischemia). The brutal reperfusion of the graft exposes it to reperfusion injury that
      causes PGF. PGF occurs in up to 20% of transplanted patients and is associated with
      significantly higher levels of 30-days all-cause mortality. Patients with PGF have a 40%
      mortality at 30-days versus a 6% mortality in patients without PGF.

      Ischemic postconditioning, has recently been described in experimental models of
      ischemia-reperfusion injury in the heart, and although not yet fully understood. Several
      studies suggest that the mitochondria play a central role in cellular survival mechanisms
      after a prolonged period of ischemia-reperfusion (with the mitochondrial permeability
      transition pore (mPTP)).

      Experimental studies have shown that cyclosporin A (CsA) administered prior to reperfusion
      binds to cyclophilin D and blocks the opening of mPTP after reperfusion. This protective
      effect of ischemia-reperfusion injury by CsA has been shown in experimental studies and in
      clinical phase II trials in reperfused myocardial infarction patients.

      The hypothesis of this study is that the administration of CsA in transplanted patients
      (before re-opening of the first pulmonary graft vessels) protects the transplanted lung(s)
      from the deleterious effects of ischemia-reperfusion injury and thus reduce the frequency and
      severity of PGF.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio (ratio of arterial oxygen partial pressure to fractional inspired oxygen)</measure>
    <time_frame>2 hours post-lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>6 hours post-lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>12 hours post-lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>18 hours post-lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>24 hours post-lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>36 hours post-lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>48 hours post-lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>60 hours post-lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>72 hours post-lung transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>primary graft failure grade</measure>
    <time_frame>72 hours</time_frame>
    <description>clinical status of primary graft failure at 72 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion</description>
    <arm_group_label>Cyclosporine A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients over 18 years old, man or woman, who are listed for pulmonary
             transplantation either mono or double lung transplantation.

        Exclusion Criteria:

          -  No contra-indication to CsA administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François TRONC, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François TRONC, Pr</last_name>
    <phone>4 72 35 74 84</phone>
    <phone_ext>+33</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel OVIZE</last_name>
    <phone>4 27 85 65 70</phone>
    <phone_ext>+33</phone_ext>
    <email>michel.ovize@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Ovize</last_name>
      <email>michel.ovize@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung transplantation</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Postconditioning</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

